Abstract
Magnetic resonance imaging (MRI) is the key prognostic tool in people with a clinically isolated syndrome (CIS). There is increasing interest in treating people following a CIS in the hope that conversion to multiple sclerosis (MS) will be prevented and future disability reduced. So far, the prognostic value of MRI for disability following a CIS has not been evaluated systematically. We systematically searched MEDLINE and EMBASE. Cohort studies were selected if they reported associations of MRI and disability following a CIS, included at least 50 people with a CIS at baseline, had at least 5 years of follow-up and obtained at least one structural MRI measurement (T1 lesions, T2 lesions, T1 contrast-enhancing lesions or brain atrophy). We assessed the studies for quality and rated the completeness of MRI reporting. In total, 13 studies were identified reporting on the following: T2 lesion number and volume, T2 infratentorial lesion number and volume, T1 contrast-enhancing lesions and grey matter fraction. T2 brain lesion number determined soon after the occurrence of a CIS was associated with disability progression after 5-7 years, with an increased risk when 10 or more lesions were present. Infratentorial lesions were also associated with a higher risk of subsequent disability. The number and distribution of MRI-visible lesions soon after a CIS are associated with disability later on, and may offer additional useful information when making treatment decisions in people with early MS. Further work is required to determine whether other measures have a higher predictive potential.
| Original language | English |
|---|---|
| Journal | Acta Neurologica Scandinavica |
| Volume | 139 |
| Issue number | 1 |
| Pages (from-to) | 18-32 |
| Number of pages | 15 |
| ISSN | 0001-6314 |
| DOIs | |
| Publication status | Published - 01.2019 |
Funding
This study was funded by the German Federal Ministry of Education and Research within the Competence Network Multiple Sclerosis (Kompetenznetz Multiple Sklerose, 01GI1206). The funding body had no influence on the design, administration, analysis and interpretation, as well as the dissemination of results of this study. SK has nothing to declare. AR was funded by German Ministry of Education and Research and received sponsorship from the University of Hamburg (equalisation fund) and is supported by a research grant from the National MS Society, USA (grant no. G-1508-06034). IS was supported by a research grant from the National MS Society, USA (grant no. G-1508-06034). CH has received research grants, congress travel compensations and salaries for talks from BiogenIdec, Genzyme, Sanofi-Aventis, Bayer Healthcare, Merck Serono, Teva Pharma and Novartis. CL received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no. 01GI1601I; has received consulting and speaker’s honoraria from BiogenIdec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA; and has received research scientific grant support from Bayer Schering, TEVA and Merck Serono. He holds an endowed professorship supported by the Novartis Foundation. DC has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work, Teva for advisory board work, meeting expenses from Merck, Teva, Novartis, the MS Trust and National MS Society, and has previously held stock in GlaxoSmithKline. JPS receives research funding from the German Research Foundation, reports grants and travel funding and/or speaker honoraria from Biogen and Genzyme outside the submitted work and was supported by a research grant from the National MS Society, USA (grant no. G-1508-06034).
| Funders | Funder number |
|---|---|
| Competence Network Multiple Sclerosis | 01GI1206 |
| German Federal Ministry of Education and Research | |
| MS Trust and National MS Society | |
| Novartis Pharma | |
| Ismar Healthcare | |
| Sanofi | |
| Bayer Schering | |
| Swiss MS Society | |
| Bundesministerium für Bildung und Forschung | |
| Bayer | |
| Merck Serono | |
| Genzyme | |
| German Federal Ministry for Education and Research | |
| German Ministry of Education and Research | |
| TEVA | |
| German Competence Network Multiple Sclerosis | 01GI1601I |
| Genzyme | |
| Novartis Foundation | |
| GlaxoSmithKline | |
| previously Serono Symposia International Foundation | |
| Deutsche Forschungsgemeinschaft | |
| National Multiple Sclerosis Society | |
| University of Hamburg |
Research Areas and Centers
- Research Area: Center for Population Medicine and Public Health (ZBV)
- Academic Focus: Biomedical Engineering
DFG Research Classification Scheme
- 2.22-02 Public Health, Healthcare Research, Social and Occupational Medicine
- 2.22-32 Medical Physics, Biomedical Technology